Novartis to expand US-based manufacturing and R&D footprint with investment of $23B over the next 5 years
On Apr. 10, 2025, Novartis, a leading global innovative medicines company, announced a planned $23 billion investment over…
Artificial Intelligence | Biotechnology | Diagnostics | Life Science News | Neurology | Therapeutics
Scientists complete largest wiring diagram and functional map of the brain to date
On Apr. 9, 2025, a team of neuro scientists scientists published findings from the Machine Intelligence from Cortical…
Merck buys rights to heart disease drug in latest China deal worth up to $2 billion
On Mar. 25, 2025, Merck announced it has signed a licensing agreement for a heart disease drug with…
Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
On Mar. 14, 2025, Sanofi announced the immediate adoption of influenza strains selected by the U.S. Food and…
Researchers bend DNA strands with light, revealing a new way to study the genome
On Sep. 9, 2024, a Princeton University team announced they had developed a way to probe chromosomes and…
CSL’s Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrated Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B
On Dec. 10, 2022, CSL announced data affirming the long-term durability and safety of single-infusion HEMGENIX® (etranacogene dezaparvovec-drlb)…
Innovation Pharmaceuticals reported Brilacidin inhibited Omicron, Delta, Gamma and Alpha SARS-CoV-2 variants
On Jun. 23, 2022, Innovation Pharmaceuticals reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity,…
USDA confirmed highly pathogenic Avian influenza in New Jersey
On May 18, 2022, the U.S. Department of Agriculture’s (USDA) Animal and Plant Health Inspection Service (APHIS) confirmed…
USDA issued a conditional license for mink Coronavirus
On Apr. 27, 2022, the U.S. Department of Agricultureﾒs Animal and Plant Health Inspection Service announced it had…
Sanofi and Parkinson’s Foundation collaborated to advance availability of free genetic testing and counseling for people with Parkinson’s disease
On Jun. 1, 2021, Sanofi announced that Vaxelis (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus…
The US Department of Defense identified more troops to help administer COVID-19 vaccine
On Mar. 10, 2021, the U.S. Department of Defense (DOD) announced that it had identified additional personnel authorized…
COVID-19 reduced US life expectancy, especially among Black and Latino populations
On Jan. 14, 2021, USC and Princeton researchers reported that the COVID-19 pandemic, which claimed more than 336,000…
Cue’s Molecular, point-of-care COVID-19 tests deployed to five states in HHS and DOD pilot program
On Nov. 19, 2020, Cue Health announced that, as of November 9, the U.S. Department of Health and…
Seqirus began shipping 2020/21 influenza vaccines to U.S. market
On Jul. 30, 2020, Seqirus announced it had begun shipping its portfolio of seasonal influenza vaccines to customers…
ViralClear opened enrollment with first patient dosing in phase II human trial of anti-viral MMPD oral solution for treatment of COVID-19
On Jun. 17, 2020, BioSig Technologies, and its subsidiary, ViralClear, announced that it had commenced patient enrollment with…
The FDA issued EUA for first diagnostic test using at-home collection of saliva specimens
On May 8, 2020, the FDA issued an emergency use authorization (EUA) to Rutgers Clinical Genomics Laboratory for…
New virus detection process under development at Rutgers-Camden
On Apr. 21, 2020,the fight against the coronavirus is underway in a Rutgers UniversityﾖCamden research laboratory, where chemistry…
More than 800 employees from Rutgers, Robert Wood Johnson University Hospital and University Hospital participate in a pioneering study
On Apr. 21, 2020, Rutgers University announced it has launched the nation’s largest prospective study of health care…
Pluristem treated first COVID-19 patient in US under FDA single patient expanded access program
On Apr. 13, 2020, Pluristem Therapeutics announced it has treated its first patient suffering from COVID-19 complications in…
Merck donated 300,000 masks to New Jersey for COVID-19 emergency response
On Mar. 25, 2020, Merck announced it had donated 300,000 masks to New Jersey’s Office of Homeland Security…
New COVID-19 assay adapted to run on T2 Biosystems’ FDA-cleared T2Dx Instrument
On Mar. 24, 2020, T2 Biosystems announced it had entered into a worldwide licensing agreement for a rapid…
T2 Biosystems announced worldwide licensing agreement of COVID-19, novel Coronavirus assay
On Mar. 24, 2020, T2 Biosystems announced it has entered into a worldwide licensing agreement for a rapid…
Acura Pharmaceuticals provides an update on the development of LTX-03
On Mar. 23, 2020, Acura Pharmaceuticals announced that Abuse Deterrent Pharma, its licensee of LTX-03 (Hydrocodone Bitartrate and…
Research revealed new coronavirus stable for hours on surfaces
On Mar. 17, 2020, the virus that causes coronavirus disease 2019 (COVID-19) was stable for several hours to…
BioReference Laboratories and State of New Jersey provided testing for Coronavirus 2019
On Mar. 20, 2020, BioReference Labs, an OPKO Health company, announced a collaboration with the State of New…
FDA approved Fluad Quadrivalent (influenza vaccine, adjuvanted; Seqirus) for adults 65 years and older
On Feb. 24, 2020, Seqirus announced that the U.S. Food and Drug Administration (FDA) had approved the first…
Biotechnology | COVID-19 | Infectious Disease | Life Science News | Therapeutics | Vaccine | Women's Health
Sorrento and Celularity to initiate emergency allogeneic natural killer cell therapy development for Coronavirus infection
On Jan. 29, 2020, Sorrento Therapeutics announced it had initiated a clinical and manufacturing collaboration with Celularity, a…
Seqirus’ Received Health Canada approval of first cell-based seasonal influenza vaccine
On Dec. 11, 2019, Seqirus announced that its cell-based quadrivalent influenza vaccine (QIVc) had received approval from Health…
Seqirus’ Next Generation Cell-based Influenza Vaccine Shows Significantly Greater Effectiveness Compared to Standard Egg-based Options in the 2017-18 US Influenza Season
On Dec. 5, 2018, Seqirus, a CSL subsidiary, announced real-world data showing that its cell-based quadrivalent influenza vaccine…
Teva Pharmaceuticals announced North America headquarters moved to New Jersey
On Jul. 6, 2018, Teva Pharmaceuticals announced it would move its U.S. headquarters to Parsippany-Troy Hills, New Jersey…